Sage Journals: Discover world-class research

Abstract

Objective

Seasonal allergic rhinitis (SAR) is a highly prevalent disease. This study was conducted to evaluate the onset and duration of action of three concentrations of olopatadine nasal spray.

METHODS

This was a randomized, double-blind, single-dose, placebo-controlled study, conducted in an environmental exposure chamber in patients with SAR. A total of 320 patients were exposed to ragweed allergen in the chamber and randomized to olopatadine nasal spray 0.2%, 0.4%, 0.6%, or placebo nasal spray. Symptoms (sneezing, runny, itchy, and stuffy nose) were self-assessed during a 12-hour study period.

RESULTS

All concentrations of olopatadine nasal spray provided clinically meaningful reductions in total nasal symptom scores at 30 minutes compared to the placebo. Olopatadine nasal spray 0.6% was significantly more effective (P <0.05) than placebo nasal spray at all time-points starting at 90 minutes postdose and continuing over 12 hours.

CONCLUSIONS

Olopatadine nasal spray 0.6% demonstrated a fast onset of action and maintained an effect for at least 12 hours after dosing.

Get full access to this article

View all access options for this article.

References

Dykewicz

, Fineman S eds., and the Working Group on Rhinitis. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma, and immunology. Ann Allergy Asthma Immunol 1998; 81:478–518.

Hollingsworth

HM.

Allergic rhinoconjunctivitis: current therapy.

Hosp Pract 1996; 31:61–2, 65–7, 71–3.

AAFA Allergy Survey, Harris Interactive, Inc. 2005.

Yanni

Stephens

Miller

The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 1996; 12:389–400.

Abelson

Spitalny

Combined analysis of two studies using conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998; 125:797–804.

U.S. Food and Drug Administration. Draft guidance for allergic rhinitis: clinical development programs for drug products (http://www.fda.gov/cder/index.html). Publication #2718dft, 2000; accessed June 2, 2006.

McNeeley

Wiseman

LR.

Intranasal azelastine: a review of its efficacy in the management of allergic rhinitis. Drugs 1998; 56:91–114.

Neilsen

Dahl

Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials. Am J Respir Med 2003; 2:55–65.

Ratner

Hampel

Amar

Safety and efficacy of ol-opatadine hydrochloride nasal spray for the treatment of seasonal (mountain cedar) allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95:474–9.

10.

Meltzer

Hampel

Ratner

Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95:600–6.

11.

Day

Briscoe

Rafeiro

Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergy rhinitis studied in a controlled exposure model. J Allergy Clin Immunol 2000; 105:489–94.

An assessment of the onset and duration of action of olopatadine nasal spray